Compare CSV & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CSV | ANL |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 643.0M | 611.1M |
| IPO Year | 1996 | 2022 |
| Metric | CSV | ANL |
|---|---|---|
| Price | $37.88 | $10.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $59.00 | $20.00 |
| AVG Volume (30 Days) | 125.5K | ★ 176.5K |
| Earning Date | 05-06-2026 | 04-10-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 54.76 | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $417,440,000.00 | N/A |
| Revenue This Year | $7.35 | $36.02 |
| Revenue Next Year | $3.87 | N/A |
| P/E Ratio | $45.32 | ★ N/A |
| Revenue Growth | ★ 3.28 | N/A |
| 52 Week Low | $37.11 | $0.88 |
| 52 Week High | $52.10 | $17.25 |
| Indicator | CSV | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 41.74 | 44.82 |
| Support Level | $37.13 | $9.00 |
| Resistance Level | $44.62 | $9.98 |
| Average True Range (ATR) | 1.13 | 1.41 |
| MACD | 0.17 | 0.03 |
| Stochastic Oscillator | 28.42 | 40.46 |
Carriage Services Inc is a provider of funeral and cemetery services and merchandise in the United States. It operates in two business segments: The Funeral Home Operations segment offers burial, cremation, and consultation services; removes and prepares remains; sells caskets, urns, and related funeral merchandise. The company enables the use of funeral home facilities for visitation, remembrance, and transportation services. The Cemetery Operations segment provides services, such as mausoleum spaces and niches, private estates, lawn crypt gardens, traditional single burial gravesites, and burial vaults. The majority of revenue is derived from The Funeral Home Operations segment.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.